Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51results about How to "Reducing food intake" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dynamic nerve stimulation for treatment of disorders
ActiveUS20050065575A1Provide central nervous system satietyIncreased energy expenditureSpinal electrodesDiseasePhysical therapy
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.
Owner:ADVANCED NEUROMODULATION SYST INC
Wireless electric modulation of sympathetic nervous system
InactiveUS7236822B2Increased energy expenditureReducing food intakeInternal electrodesExternal electrodesDiseaseNervous system
A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC
Hybrid polypeptides with selectable properties
ActiveUS20060293232A1Reverse glucose intoleranceIncrease massNervous disorderPeptide/protein ingredientsBlood lipidsGestational diabetes
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP
Electric modulation of sympathetic nervous system
InactiveUS7239912B2Increase energy expenditureReduce food intakeInternal electrodesExternal electrodesNervous systemAdrenal tissue
A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC
Dynamic nerve stimulation for treatment of disorders
ActiveUS7689276B2Increased energy expenditureReducing food intakeSpinal electrodesDiseasePhysical therapy
Owner:ADVANCED NEUROMODULATION SYST INC
Methods and compositions for oral administration of exenatide
InactiveUS20110046053A1Reducing food intakeDecreased gastric motilityPeptide/protein ingredientsMetabolism disorderDiabetes mellitusOral medication
This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.
Owner:ORAMED
Dynamic nerve stimulation in combination with other eating disorder treatment modalities
InactiveUS20080262411A1Provide central nervous system satietyIncreased energy expenditureBiocideOrganic active ingredientsDiseaseWeight-loss drugs
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC
Splanchnic nerve stimulation for treatment of obesity
InactiveUS7551964B2Increased energy expenditureReducing food intakeElectrotherapyArtificial respirationDiseaseSplanchnic nerve stimulation
Owner:ADVANCED NEUROMODULATION SYST INC
Large-scale process for the preparation of thylakoids
InactiveUS20110182930A1Increase satietyLose weightBiocideMetabolism disorderBlood insulinDietary supplement
The present invention relates to a process on a large industrial scale for the production of thylakoids, from photosynthetic organisms, such as from green plant leaf material, to be used as ingredients in food, or additions to food, or dietary supplements, or pharmaceuticals for the purpose of preventing overweight, promoting satiety, reducing food intake, reducing bodyweight, reducing blood insulin concentration and reducing blood fats and percentage body fat in humans and animals.
Owner:THYLABISCO
Hybrid Polypeptides with Selectable Properties
InactiveUS20090286723A1Reverse glucose intoleranceIncrease massSenses disorderPeptide/protein ingredientsBlood lipidsEating disorders
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP
Dynamic nerve stimulation in combination with other eating disorder treatment modalities
ActiveUS20100106207A1Provide central nervous system satietyIncreased energy expenditureOrganic active ingredientsElectrotherapyDiseaseWeight-loss drugs
A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC
Melanocortin receptor-specific peptides
InactiveUS20100311648A1Reducing food intakeReducing body weight body gainNervous disorderMetabolism disorderOverweightDisease
The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I)or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and / or energy balance and body weight related diseases, disorders and / or conditions, including obesity, overweight and diseases, disorders and / or conditions associated with obesity and / or overweight, such as type 2 diabetes and metabolic syndrome.
Owner:ASTRAZENECA AB
Splanchnic Nerve Stimulation for Treatment of Obesity
InactiveUS20100234907A1Increased energy expenditureReducing food intakeSpinal electrodesArtificial respirationSplanchnic nerve stimulationDisease
Owner:DOBAK III JOHN D
Splanchnic nerve stimulation for treatment of obesity
InactiveUS20090259279A1Provide central nervous system satietyIncreased energy expenditureSpinal electrodesArtificial respirationDiseaseSplanchnic nerve stimulation
A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.
Owner:DOBAK III JOHN D
Dynamic nerve stimulation in combination with other eating disorder treatment modalities
ActiveUS8295926B2Increased energy expenditureReducing food intakeOrganic active ingredientsElectrotherapyDiseaseWeight-loss drugs
A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC
Methods and compositions for oral administration of exenatide
ActiveUS20130195939A1Reducing food intakeDecreased gastric motilityPeptide/protein ingredientsSkeletal disorderDiabetes mellitusOral medication
Owner:ORAMED
Combination of a certain dpp-4 inhibitor and voglibose
InactiveUS20140343014A1Improving glycemicImproving body weight controlBiocideMetabolism disorderDiseaseGlycosidase inhibitor
The present invention relates to the use of a combination of a certain DPP-4 inhibitor and an alpha-glucosidase inhibitor for use in therapy, e.g. for use in treating and / or preventing a metabolic disease such as type 2 diabetes mellitus and / or conditions related thereto. The invention also relates to the use of such combination for improving body weight control, reducing body weight, inducing satiety, inhibiting gastric emptying and / or reducing food intake, in a patient in need thereof.
Owner:BOEHRINGER INGELHEIM INT GMBH
Composition and Method for Reducing Food Intake
InactiveUS20120121735A1Appetite suppressantIncrease metabolic rateBiocideMetabolism disorderDietary fiberGastric emptying
Owner:SWISS RES LABS
Transdermal system for extended delivery of incretins and incretn mimetic peptides
InactiveUS20110129522A1Reduce appetiteLowering plasma lipidPeptide/protein ingredientsMetabolism disorderTransdermal patchViscous liquid
A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject.
Owner:SYNERON MEDICAL LTD
Electric modulation of sympathetic nervous sytem
InactiveUS20070219596A1Increased energy expenditureReducing food intakeInternal electrodesExternal electrodesDiseaseNervous system
A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
Owner:LEPTOS BIOMEDICAL
Long-acting glp-1/glucagon receptor agonists
PendingUS20140349922A1Reduce insulin resistanceImproved biologicalPeptide/protein ingredientsMetabolism disorderAgonistPharmacology
Pegylated and reverse pegylated GLP-1 / Glucaron receptor agonists including pharmaceutical compositions comprising the same and methods of using the same are disclosed.
Owner:OPKO BIOLOGICS
Compositions incorporating(-)-hydroxycitric acid and related methods for promoting fat oxidation
InactiveUS7335651B2Good for weight lossReduce appetiteBiocideHeavy metal active ingredientsSerum igeGymnemic acid
Owner:LONZA CONSUMER HEALTH INC
Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
InactiveUS20100004166A1Reduce food intakeInduce satietyPeptide/protein ingredientsMetabolism disorderFeeding disorderInsulin resistance
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an endothelin or an endothelin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:AMYLIN PHARMA INC
Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
InactiveUS20050008726A1Increased serotonin levelReducing leptin levelHeavy metal active ingredientsBiocideSerotoninGymnemic acid
Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.
Owner:INTERHEALTH NUTRACEUTICALS
Endoscopic gastric mucosal ablation/resection/exclusion (a/r/e) as a minimally invasive weight loss approach
ActiveUS20170367723A1Reducing stomach capacityReduce in quantityEndoscopesSurgical instruments for heatingPresent methodEndoscopy
The present invention is directed to a method of endoscopically ablating / resecting / excluding (A / R / E) the mucosa of the gastric fundus and body. The method of the present invention is intended to cause cellular death to the X / A-like, ghrelin producing and other hormone cells. This is in contrast to present methods to provide only transient ischemia. The use of the method of the present invention results in a more permanent and robust method of reducing ghrelin and other hormone levels. In addition, a method according to the present invention can be used to induce scarring of the gastric fundus which will reduce gastric accommodation of excess food and result in early satiety.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Splanchnic Nerve Stimulation For Treatment of Obesity
InactiveUS20100145408A1Increased energy expenditureReducing food intakeSpinal electrodesArtificial respirationSplanchnic nerve stimulationDisease
Owner:DOBAK III JOHN D
Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity
InactiveUS20150182597A1Increase insulin sensitivityInhibit expressionBiocideOrganic active ingredientsDermatan sulfateWeight gain
The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate. The composition can be in the form of a pharmaceutical composition, a food, a functional food, a medical food or a food supplement.
Owner:BIOIBI12RICA
Compositions and methods for inducing satiety and reducing caloric intake
InactiveUS20090053680A1Good for weight lossReducing food intakeDigestive systemFood ingredient functionsMedicineSoluble fiber
A method is provided for determining the eating restraint behavior of an individual and communicating a recommendation to the individual based on the eating restraint behavior for compositions to consume that effective for the diagnosed eating restraint behavior. Such compositions effective for low rigid restraint eaters include soluble fiber and a multivalent cation.
Owner:MCNEIL NUTRITIONALS
Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
InactiveUS20050008725A1Increased serotonin levelReducing leptin levelBiocideHeavy metal active ingredientsMammalCholesterol
Methods for promoting healthy body weight and improving a variety of related physiological factors, including serum serotonin levels, serum leptin levels, fat oxidation, cholesterol levels, and body mass index, in persons or other mammals, include administering to those persons or other mammals effective amounts of hydroxycitric acid or a combination of hydroxycitric acid, chromium and gymnemic acid, which work synergistically to further to promote healthy body weight and improve these physiological factors.
Owner:INTERHEALTH NUTRACEUTICALS
Novel polypeptide and therapeutic uses thereof
PendingUS20220127323A1Unexpected effectInhibit progressPeptide-nucleic acidsPeptide/protein ingredientsPeptide chemistryBiochemistry
The invention relates to the field of peptide chemistry, in particular, the invention relates to a peptide compound and its use in medical treatment.
Owner:VITALIXIR BEIJING CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com